Year None20222021202020192018 May 17, 2022 Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference May 12, 2022 Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress May 04, 2022 Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results Apr 08, 2022 Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR Mar 08, 2022 Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022 Mar 01, 2022 Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference Feb 24, 2022 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results Feb 01, 2022 Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
May 12, 2022 Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
Apr 08, 2022 Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
Mar 08, 2022 Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
Feb 24, 2022 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
Feb 01, 2022 Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development